Stock Price
P/E Ratio
Volume Traded Today
Dividend
52 Week High/low
IO Biotech, Inc. Market Cap
Based on ratings from 5 stock analysts, the IO Biotech, Inc. stock price is expected to increase by 911.24% in 12 months. This is calculated by using the average 12-month stock price forecast for IO Biotech, Inc.. The lowest target is $6 and the highest is $12. Please note analyst price targets are not guaranteed and could be missed completely.
About 5 Wall Street analysts have assigned IOBT 5 buy ratings, 0 hold ratings, and 0 sell ratings. This means that analysts expect IO Biotech, Inc. to outperform the market. Keep in mind that these ratings are typically refreshed every quarter, underscoring the importance of conducting your own research on IOBT. Don't forget to include both technical and fundamental analysis, as well as staying informed on news that could influence these ratings, in your due diligence.
These are the latest 20 analyst ratings of IOBT.
|
Analyst/Firm |
Rating |
Price Target |
Change |
Date |
|---|---|---|---|---|
| Emily Bodnar HC Wainwright & Co. | Buy | $12 | Reiterates | Nov 12, 2024 |
| Emily Bodnar HC Wainwright & Co. | Buy | $12 | Reiterates | Nov 6, 2024 |
| Emily Bodnar HC Wainwright & Co. | Buy | $12 | Reiterates | Sep 16, 2024 |
| Matthew Harrison Morgan Stanley | Overweight | $6 | Maintains | Sep 16, 2024 |
| Christopher Raymond Piper Sandler | Overweight | $10 | Maintains | Sep 3, 2024 |
| Emily Bodnar HC Wainwright & Co. | Buy | $12 | Reiterates | Sep 3, 2024 |
| Matthew Harrison Morgan Stanley | Overweight | $4 | Maintains | Sep 3, 2024 |
| Emily Bodnar HC Wainwright & Co. | Buy | $12 | Reiterates | Aug 14, 2024 |
| Emily Bodnar HC Wainwright & Co. | Buy | $12 | Maintains | May 15, 2024 |
| Emily Bodnar HC Wainwright & Co. | Buy | $8 | Reiterates | Mar 6, 2024 |
| Christopher Raymond Piper Sandler | Overweight | $10 | Initiates | Sep 28, 2023 |
| Emily Bodnar HC Wainwright & Co. | Buy | $8 | Reiterates | Sep 13, 2023 |
| Matthew Harrison Morgan Stanley | Overweight | $7 | Maintains | Aug 15, 2023 |
| Emily Bodnar HC Wainwright & Co. | Buy | $8 | Reiterates | Aug 11, 2023 |
| Emily Bodnar HC Wainwright & Co. | Buy | $10 | Reiterates | Mar 15, 2023 |
| Matthew Harrison Morgan Stanley | Overweight | $11 | Maintains | Jan 24, 2023 |
| Emily Bodnar HC Wainwright & Co. | Buy | $10 | Initiates | Nov 21, 2022 |
| Chris Howerton Jefferies | Buy | $20 | Initiates | Nov 30, 2021 |
| Matthew Harrison Morgan Stanley | Overweight | $21 | Initiates | Nov 30, 2021 |
| Yaron Werber Cowen & Co. | Outperform | Initiates | Nov 30, 2021 |
When did it IPO
2021
Staff Count
74
Country
Denmark
Sector/Industry
Healthcare/Biotechnology
CEO
Dr. Mai-Britt Zocca Ph.D.
Market Cap
$58.6M
In 2023, IOBT generated $0 in revenue, which was a increase of 0.00% from the previous year. This can be seen as a signal that IOBT's business is growing, and its share price could be worth more in the future. However, if the company grows faster (or slower) than expected, this could also have a major impact on the future share price.
Revenue From 2020
Revenue From 2021
Revenue From 2022
Revenue From 2023
Tue, 12 Nov 2024
Sentiment - NEUTRAL
Source - GlobeNewsWire
Summary - IO Biotech's Phase 3 trial for its cancer vaccine IO102-IO103 with KEYTRUDA is on track for 2025. Phase 2 trials show positive results. The company has $80M in cash, funding operations into Q4 2025.
Why It Matters - The successful Phase 3 trial progress and strong cash position signal potential growth and sustainability for IO Biotech, influencing investor confidence and stock performance.
Mon, 11 Nov 2024
Sentiment - NEUTRAL
Source - GlobeNewsWire
Summary - IO Biotech (Nasdaq: IOBT) will participate in the Jefferies London Healthcare Conference on November 20 and the Piper Sandler Healthcare Conference on December 3, featuring CEO Mai-Britt Zocca.
Why It Matters - IO Biotech's upcoming conferences highlight its commitment to investor engagement and could signal potential market interest in its innovative cancer vaccine, impacting stock performance.
Thu, 07 Nov 2024
Sentiment - NEUTRAL
Source - GlobeNewsWire
Summary - IO102-IO103 combined with Keytruda® in metastatic NSCLC showed a 55% unconfirmed, 48% confirmed overall response rate and 81% disease control rate. Safety profile was consistent with prior studies.
Why It Matters - Promising clinical results for IO102-IO103 combined with Keytruda in NSCLC enhance market confidence, potentially boosting stock values for the involved biotech companies and impacting healthcare investments.
Fri, 04 Oct 2024
Sentiment - NEUTRAL
Source - GlobeNewsWire
Summary - IO Biotech (Nasdaq: IOBT) announced two abstracts accepted for poster presentation at SITC 2024, scheduled for November 8-10 in Houston, showcasing its immune-modulating cancer vaccines.
Why It Matters - The acceptance of two abstracts for presentation at a major cancer conference highlights IO Biotech's credibility and innovation, potentially influencing stock performance and investor sentiment.
Sat, 14 Sep 2024
Sentiment - NEUTRAL
Source - GlobeNewsWire
Summary - A study on Squamous Cell Carcinoma of the Head and Neck met its primary endpoint for overall response rate and showed positive progression-free survival data, with no new safety concerns reported.
Why It Matters - Positive study results indicate potential for effective treatment in head and neck cancer, which may boost the company's stock value and attract interest from investors.
Fri, 30 Aug 2024
Sentiment - NEUTRAL
Source - GlobeNewsWire
Summary - The IDMC has recommended continuing the trial with no modifications, noting no new safety issues. Primary endpoint of progression-free survival expected by mid-2025.
Why It Matters - The trial's continuation and lack of new safety signals boost confidence in the drug's potential, positively influencing stock valuations and investor sentiment.
The information that Ticker Nerd provides is general in nature as it has been prepared without taking account of your objectives, financial situation or needs. It is not intended as legal, financial or investment advice and should not be construed or relied on as such. Ticker Nerd is for information purposes only. Ticker Nerd is not responsible for any damages or losses that may occur as a result of reliance on this information. Before making any commitment of a legal or financial nature you should seek advice from a qualified and registered legal practitioner or financial or investment adviser. All content, group, messaging, tweets, newsletter, article, and email created by Ticker Nerd is intended for educational and information purposes only, is not financial, investment, legal or tax advice, and is a restatement, summary or extract of other data and research reports that are widely distributed from sources such as, but not limited to, Bloomberg, Market Watch, Wall Street Journal, Google Finance, and Yahoo Finance. Ticker Nerd is not a registered financial, investment, legal or tax advisor and is not liable for any financial loss you may incur acting on any information provided by Ticker Nerd. By registering, you agree not to hold Ticker Nerd liable at any time or under any circumstances for your decisions, actions, or results.
